Payment overview · 2025
General Payments
$481.80
27 reported records · 14 companies
Healthcare provider profile · identity verified
Pamela W Wright, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · STUART, VA · NPI 1164739751
Verified facts
What the public records show
CMS Open Payments records show Pamela W Wright, NP received $481.80 in general payments during 2025 across 27 reported records.
GENZYME CORPORATION accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Nurtec Odt, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tezspire by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $113.54 | 23.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.71 | 15.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.93 | 14.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.17 | 11.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.34 | 6.5% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.63 | 4.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.63 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.46 | 3.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.93 | 3.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.75 | 3.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.08 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.92 | 2.9% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.86 | 2.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.85 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $481.80 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $113.54 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.71 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $57.60 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.50 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $30.96 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 66 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 102 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 88 |
| Omeprazole | Omeprazole | 288 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 78 |
| Gabapentin | Gabapentin | 225 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 220 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 203 | 55 |
| Lisinopril | Lisinopril | 201 | 57 |
| Metformin Hcl Er | Metformin Hcl | 201 | 61 |
| Tizanidine Hcl | Tizanidine Hcl | 186 | 54 |
| Alprazolam | Alprazolam | 181 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 50 |
| Furosemide | Furosemide | 176 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 157 | 46 |
| Losartan Potassium | Losartan Potassium | 153 | 36 |
| Ozempic | Semaglutide | 152 | 23 |
| Buspirone Hcl | Buspirone Hcl | 148 | 41 |
| Sertraline Hcl | Sertraline Hcl | 147 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 35 |
| Trazodone Hcl | Trazodone Hcl | 119 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 116 | 21 |
| Famotidine | Famotidine | 111 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 30 |
| Farxiga | Dapagliflozin Propanediol | 102 | 26 |
| Tramadol Hcl | Tramadol Hcl | 100 | 18 |
| Potassium Chloride | Potassium Chloride | 94 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 27 |
| Nystatin | Nystatin | 91 | 41 |
| Diazepam | Diazepam | 88 | 19 |
| Metformin Hcl | Metformin Hcl | 87 | 30 |
| Carvedilol | Carvedilol | 86 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 16 |
| Montelukast Sodium | Montelukast Sodium | 82 | 26 |
| Sucralfate | Sucralfate | 80 | 23 |
| Pregabalin | Pregabalin | 79 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 22 |
| Allopurinol | Allopurinol | 74 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 62 |
| Methocarbamol | Methocarbamol | 69 | 23 |
| Prazosin Hcl | Prazosin Hcl | 68 | 17 |
| Eliquis | Apixaban | 66 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 23 |
| Alendronate Sodium | Alendronate Sodium | 61 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 61 | 20 |
| Ibuprofen | Ibuprofen | 61 | 15 |
| Azithromycin | Azithromycin | 60 | 44 |
| Memantine Hcl | Memantine Hcl | 59 | 16 |
| Ondansetron Odt | Ondansetron | 59 | 23 |
| Tresiba Flextouch U-200 | Insulin Degludec | 58 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 12 |
| Celecoxib | Celecoxib | 52 | 11 |
| Propranolol Hcl | Propranolol Hcl | 50 | 16 |
| Simvastatin | Simvastatin | 49 | 13 |
| Fluconazole | Fluconazole | 48 | 25 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Roflumilast | Roflumilast | 48 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 44 | 44 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | 11 |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Meloxicam | Meloxicam | 40 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Prednisone | Prednisone | 39 | 24 |
| Promethazine Hcl | Promethazine Hcl | 39 | 14 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 31 |
| Glimepiride | Glimepiride | 38 | suppressed |
| Linzess | Linaclotide | 38 | 12 |
| Naproxen | Naproxen | 38 | suppressed |
| Rybelsus | Semaglutide | 38 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Acyclovir | Acyclovir | 34 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Cephalexin | Cephalexin | 25 | 24 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 19 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Prolia | Denosumab | 21 | 13 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Acarbose | Acarbose | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Metronidazole | Metronidazole | 14 | 14 |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Tezspire | Tezepelumab-Ekko | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $481.80 · 27 records | GENZYME CORPORATION | AJOVY, DUPIXENT, ELIQUIS, EVENITY, FARXIGA, INGREZZA, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, SYNCHROMEDII, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error